Echocardiographic Changes Associated With Sacubitril/Valsartan Therapy in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF): A Descriptive 12-Month Follow-Up Analysis
International Journal of Cardiovascular Sciences · 02.07.2026 · 39
DOI: 10.36660/ijcs.20250115 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cardiovascular Sciences, erschienen am 02.07.2026. Verfasst von Marcely Bonatto und 7 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Although randomized controlled trials have demonstrated the efficacy of Sacubitril/Valsartan in heart failure (HF), real-world evidence regarding its impact on cardiac remodeling, particularly in Heart Failure With Reduced Ejection Fraction (HFrEF), remains limited.
Objectives
This real-world study aimed to evaluate echocardiographic changes, including ejection fraction (EF), in a cohort of patients with HFrEF treated at a public hospital in Curitiba, Brazil, and to assess clinical outcomes at 6 and 12 months of follow-up.
Methods
Longitudinal data were collected from 200 patients with HFrEF at baseline and at 6- and 12-month follow-up. Echocardiographic assessments included EF, left ventricular (LV) dimensions, and other cardiac parameters. Clinical outcomes included HF-related hospitalizations and New York Heart Association (NYHA) functional class.
Results
Sacubitril/Valsartan therapy was associated with improvements in EF, with the median increasing from 28% at baseline to 31.5% at 6 months and 34% at 12 months (Teichholz method). Structural remodeling was observed, including reductions in LV end-systolic and end-diastolic dimensions, as well as left atrial (LA) diameter. HF-related hospitalization rates decreased from 31.8% at baseline to 20.6% at 6 months and 11.3% at 12 months. NYHA functional class improved, with the proportion of patients in Classes III and IV decreasing from 53.2% at baseline to 17.4% at 6 months. Renal function remained stable throughout treatment. Improvements in EF were associated with a lower risk of hospitalization at 6 months (OR = 0.95) and 12 months (OR = 0.93), whereas a larger LA diameter was associated with a higher risk of hospitalization at 12 months (OR = 1.06).
Conclusions
Sacubitril/Valsartan therapy was associated with improvements in EF, echocardiographic parameters, and NYHA functional class, as well as reductions in hospitalization rates. These findings underscore the role of the therapy in promoting reverse remodeling and suggest that its clinical benefits may extend beyond direct effects on cardiac structure.
Zitieren
APA
Bonatto, M., Freitas, A. K. E. D., Takatuzi, C. B., Franco, L. G. E., Vendramini, D. R., Lechinewski, L. D., Blume, G. G., & Moura, L. Z. (2026). Echocardiographic Changes Associated With Sacubitril/Valsartan Therapy in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF): A Descriptive 12-Month Follow-Up Analysis. International Journal of Cardiovascular Sciences, 39. https://doi.org/10.36660/ijcs.20250115
Vancouver
Bonatto M, Freitas AKED, Takatuzi CB, Franco LGE, Vendramini DR, Lechinewski LD, et al. Echocardiographic Changes Associated With Sacubitril/Valsartan Therapy in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF): A Descriptive 12-Month Follow-Up Analysis. International Journal of Cardiovascular Sciences. 2026;39. doi:10.36660/ijcs.20250115
BibTeX
@article{Bonatto2026,
author = {Bonatto, Marcely and Freitas, Ana Karyn Ehrenfried de and Takatuzi, Caio Berwanger and Franco, Luiz Gustavo Esmanhoto and Vendramini, Danielle Rodrigues and Lechinewski, Luka David and Blume, Gustavo Gavazzoni and Moura, Lidia Zytynski},
title = {Echocardiographic Changes Associated With Sacubitril/Valsartan Therapy in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF): A Descriptive 12-Month Follow-Up Analysis},
journal = {International Journal of Cardiovascular Sciences},
year = {2026},
volume = {39},
doi = {10.36660/ijcs.20250115}
}
EUVIMED